Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia
For additional information please call: 1-800-718-1021
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| torcetrapib/atorvastatin | Drug | |||
| atorvastatin | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Change in intima media thickness as measured by carotid ultrasound |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in levels of lipids and other biomarkers. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Gilbert | Arizona | United States | |||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37565307 | Derived | Clezar CN, Flumignan CD, Cassola N, Nakano LC, Trevisani VF, Flumignan RL. Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database Syst Rev. 2023 Aug 4;8(8):CD013573. doi: 10.1002/14651858.CD013573.pub2. | |
| 21613319 | Derived | Tajik P, Meijer R, Duivenvoorden R, Peters SA, Kastelein JJ, Visseren FJ, Crouse JR 3rd, Palmer MK, Raichlen JS, Grobbee DE, Bots ML. Asymmetrical distribution of atherosclerosis in the carotid artery: identical patterns across age, race, and gender. Eur J Prev Cardiol. 2012 Aug;19(4):687-97. doi: 10.1177/1741826711410821. Epub 2011 May 25. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Phoenix |
| Arizona |
| United States |
| Pfizer Investigational Site | Scottsdale | Arizona | United States |
| Pfizer Investigational Site | Alhambra | California | United States |
| Pfizer Investigational Site | Encinitas | California | United States |
| Pfizer Investigational Site | La Jolla | California | United States |
| Pfizer Investigational Site | Los Angeles | California | United States |
| Pfizer Investigational Site | San Diego | California | United States |
| Pfizer Investigational Site | Hartford | Connecticut | United States |
| Pfizer Investigational Site | Melbourne | Florida | United States |
| Pfizer Investigational Site | Palm Bay | Florida | United States |
| Pfizer Investigational Site | Sebastian | Florida | United States |
| Pfizer Investigational Site | Stuart | Florida | United States |
| Pfizer Investigational Site | Vero Beach | Florida | United States |
| Pfizer Investigational Site | Overland Park | Kansas | United States |
| Pfizer Investigational Site | Boston | Massachusetts | United States |
| Pfizer Investigational Site | Cambridge | Massachusetts | United States |
| Pfizer Investigational Site | Edina | Minnesota | United States |
| Pfizer Investigational Site | Minneapolis | Minnesota | United States |
| Pfizer Investigational Site | Kansas City | Missouri | United States |
| Pfizer Investigational Site | Concord | New Hampshire | United States |
| Pfizer Investigational Site | Bronxville | New York | United States |
| Pfizer Investigational Site | Buffalo | New York | United States |
| Pfizer Investigational Site | Mount Vernon | New York | United States |
| Pfizer Investigational Site | New York | New York | United States |
| Pfizer Investigational Site | Williamsville | New York | United States |
| Pfizer Investigational Site | Durham | North Carolina | United States |
| Pfizer Investigational Site | Raleigh | North Carolina | United States |
| Pfizer Investigational Site | Winston-Salem | North Carolina | United States |
| Pfizer Investigational Site | Cincinnati | Ohio | United States |
| Pfizer Investigational Site | Houston | Texas | United States |
| Pfizer Investigational Site | San Antonio | Texas | United States |
| Pfizer Investigational Site | Salt Lake City | Utah | United States |
| Pfizer Investigational Site | Newport News | Virginia | United States |
| Pfizer Investigational Site | Norfolk | Virginia | United States |
| Pfizer Investigational Site | Richmond | Virginia | United States |
| Pfizer Investigational Site | Bothell | Washington | United States |
| Pfizer Investigational Site | Kirkland | Washington | United States |
| Pfizer Investigational Site | Renton | Washington | United States |
| Pfizer Investigational Site | Seattle | Washington | United States |
| Pfizer Investigational Site | Vancouver | British Columbia | Canada |
| Pfizer Investigational Site | Winnipeg | Manitoba | Canada |
| Pfizer Investigational Site | Chicoutimi | Quebec | Canada |
| Pfizer Investigational Site | Montreal | Quebec | Canada |
| Pfizer Investigational Site | Québec | Quebec | Canada |
| Pfizer Investigational Site | Prague | Czechia |
| Pfizer Investigational Site | Kuopio | Finland |
| Pfizer Investigational Site | Paris | France |
| Pfizer Investigational Site | Nijmegen | Netherlands |
| Pfizer Investigational Site | Rotterdam | Netherlands |
| Pfizer Investigational Site | Utrecht | Netherlands |
| 19029469 | Derived | Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. |
| 17630038 | Derived | Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007 Jul 14;370(9582):153-160. doi: 10.1016/S0140-6736(07)61088-5. |
| 17407645 | Derived | Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML; RADIANCE 1 and 2 Study Investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin. 2007 Apr;23(4):885-94. doi: 10.1185/030079907x182121. |
| ID | Term |
|---|---|
| D006938 | Hyperlipoproteinemia Type II |
| ID | Term |
|---|---|
| D008052 | Lipid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006951 | Hyperlipoproteinemias |
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C483909 | torcetrapib |
| D000069059 | Atorvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided